Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4)

Thrombosis Research

Volumn 141, Issue , 2016, Pages 69-76

  Young, Guy ^a   Collins, Peter W ^b   Colberg, Torben ^c   Chuansumrit, Ampaiwan ^d   Hanabusa, Hideji ^e   Lentz, Steven R ^f   Mahlangu, Johnny ^g   Mauser Bunschoten, Evelien P ^h   Négrier, Claude ⁱ   Oldenburg, Johannes ^j   Patiroglu, Turkan ^k   Santagostino, Elena ^l   Tehranchi, Ramin ^c   Zak, Marek ^c   Karim, Faraizah Abdul ^m  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

^d MAHIDOL UNIVERSITY   (Thailand)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITÉ LYON 1   (France)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^l FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^m National Blood Centre   (Malaysia)

more..

Author keywords

Factor IX; Haemophilia B; Half life; Nonacog beta pegol; Prophylaxis

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; HEMOSTATIC AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTUSION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMUR FRACTURE; GASTROENTERITIS; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE RASH; LIGAMENT INJURY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MINOR SURGERY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RHINOPHARYNGITIS; SIDE EFFECT; TRAFFIC ACCIDENT; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; HEMORRHAGE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; HEMOSTATICS; HUMANS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84960333582     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2016.02.030     Document Type: Article

References (15)

1. M. Franchini, F. Frattini, S. Crestani, C. Sissa, and C. Bonfanti Treatment of hemophilia B: focus on recombinant factor IX Biologics 7 2013 33 38
2. H. Østergaard, J.R. Bjelke, L. Hansen, L.C. Petersen, A.A. Pedersen, T. Elm, and et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide Blood 118 2011 2333 2341
3. A. Gringeri, S. von Mackensen, G. Auerswald, M. Bullinger, R. Perez Garrido, E. Kellermann, and et al. Health status and health-related quality of life of children with haemophilia from six West European countries Haemophilia 10 2004 26 33
4. L.A. Valentino, L. Rusen, I. Elezovic, L.M. Smith, J.M. Korth-Bradley, and P. Rendo Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects Haemophilia 20 2014 398 406
5. P.W. Collins, J. Moss, K. Knobe, A. Groth, T. Colberg, and E. Watson Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX J. Thromb. Haemost. 10 2012 2305 2312
6. P.W. Collins, G. Young, K. Knobe, F. Abdul Karim, P. Angchaisuksiri, C. Banner, and et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial Blood 124 2014 3880 3886
7. C. Negrier, K. Knobe, A. Tiede, P. Giangrande, and J. Moss Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B Blood 118 2011 2695 2701
8. M. Escobar, T. Colberg, F. Karim, U. Caliskan, P. Chowdary, P. Giangrande, and et al. Perioperative hemostatic management of major surgery in hemophilia B with long-acting recombinant glycopegylated factor IX: results from the paradigm™3 clinical trial J. Thromb. Haemost. 13 2015 229
9. B. Verbruggen, I. Novakova, H. Wessels, J. Boezeman, M. van den Berg, and E. Mauser-Bunschoten The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability Thromb. Haemost. 73 1995 247 251
10. A.R. Mire-Sluis, Y.C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, and et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products J. Immunol. Methods 289 2004 1 16
11. G. Shankar, E. Shores, C. Wagner, and A. Mire-Sluis Scientific and regulatory considerations on the immunogenicity of biologics Trends Biotechnol. 24 2006 274 280
12. European Medicines Agency Guideline on clinical investigation of recombinant and human plasma-derived factor IX products EMA/CHMP/144552/2009 2014
13. C. Negrier, G. Young, F. Abdul Karim, P.W. Collins, H. Hanabusa, T. Colberg, and et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials Haemophilia 2016 10.1111/hae.12902
14. J.S. Powell, K.J. Pasi, M.V. Ragni, M.C. Ozelo, L.A. Valentino, J.N. Mahlangu, and et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B N. Engl. J. Med. 369 2013 2313 2323
15. E. Santagostino, M.E. Mancuso, A. Tripodi, V. Chantarangkul, M. Clerici, I. Garagiola, and et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile J. Thromb. Haemost. 8 2010 737 743